@article{Cox2018,
abstract = {Tuberculosis is the leading infectious cause of death worldwide, claiming 1.6 million lives annually.1 Antimicrobial resistance is undermining efforts to curb the global tuberculosis epidemic: among the 10.6 million cases of tuberculosis that occurred in 2016, less than a quarter of the estimated 600,000 patients with multidrug-resistant (MDR) or rifampin-resistant tuberculosis received diagnoses and were treated. Although rollout of the Xpert MTB/RIF molecular test has enabled the rapid detection of resistance to the first-line tuberculosis drug rifampin, a diagnostic test that can accurately determine the complete drug-susceptibility profile of the infecting strain or strains of Mycobacterium tuberculosis would make it . . .},
author = {Cox, Helen and Mizrahi, Valerie},
doi = {10.1056/NEJMe1811861},
journal = {New England Journal of Medicine},
keywords = {editorial,fund{\_}not{\_}ack},
mendeley-tags = {editorial,fund{\_}not{\_}ack},
month = {sep},
pages = {1474--1475},
pmid = {30256713},
publisher = {Massachusetts Medical Society},
title = {{The coming of age of drug-susceptibility testing for tuberculosis}},
url = {http://www.nejm.org/doi/10.1056/NEJMe1811861},
volume = {379},
year = {2018}
}

{"_id":"K9jwbwKpBp79Yzomi","bibbaseid":"cox-mizrahi-thecomingofageofdrugsusceptibilitytestingfortuberculosis-2018","author_short":["Cox, H.","Mizrahi, V."],"bibdata":{"bibtype":"article","type":"article","abstract":"Tuberculosis is the leading infectious cause of death worldwide, claiming 1.6 million lives annually.1 Antimicrobial resistance is undermining efforts to curb the global tuberculosis epidemic: among the 10.6 million cases of tuberculosis that occurred in 2016, less than a quarter of the estimated 600,000 patients with multidrug-resistant (MDR) or rifampin-resistant tuberculosis received diagnoses and were treated. Although rollout of the Xpert MTB/RIF molecular test has enabled the rapid detection of resistance to the first-line tuberculosis drug rifampin, a diagnostic test that can accurately determine the complete drug-susceptibility profile of the infecting strain or strains of Mycobacterium tuberculosis would make it . . .","author":[{"propositions":[],"lastnames":["Cox"],"firstnames":["Helen"],"suffixes":[]},{"propositions":[],"lastnames":["Mizrahi"],"firstnames":["Valerie"],"suffixes":[]}],"doi":"10.1056/NEJMe1811861","journal":"New England Journal of Medicine","keywords":"editorial,fund_not_ack","mendeley-tags":"editorial,fund_not_ack","month":"sep","pages":"1474–1475","pmid":"30256713","publisher":"Massachusetts Medical Society","title":"The coming of age of drug-susceptibility testing for tuberculosis","url":"http://www.nejm.org/doi/10.1056/NEJMe1811861","volume":"379","year":"2018","bibtex":"@article{Cox2018,\r\nabstract = {Tuberculosis is the leading infectious cause of death worldwide, claiming 1.6 million lives annually.1 Antimicrobial resistance is undermining efforts to curb the global tuberculosis epidemic: among the 10.6 million cases of tuberculosis that occurred in 2016, less than a quarter of the estimated 600,000 patients with multidrug-resistant (MDR) or rifampin-resistant tuberculosis received diagnoses and were treated. Although rollout of the Xpert MTB/RIF molecular test has enabled the rapid detection of resistance to the first-line tuberculosis drug rifampin, a diagnostic test that can accurately determine the complete drug-susceptibility profile of the infecting strain or strains of Mycobacterium tuberculosis would make it . . .},\r\nauthor = {Cox, Helen and Mizrahi, Valerie},\r\ndoi = {10.1056/NEJMe1811861},\r\njournal = {New England Journal of Medicine},\r\nkeywords = {editorial,fund{\\_}not{\\_}ack},\r\nmendeley-tags = {editorial,fund{\\_}not{\\_}ack},\r\nmonth = {sep},\r\npages = {1474--1475},\r\npmid = {30256713},\r\npublisher = {Massachusetts Medical Society},\r\ntitle = {{The coming of age of drug-susceptibility testing for tuberculosis}},\r\nurl = {http://www.nejm.org/doi/10.1056/NEJMe1811861},\r\nvolume = {379},\r\nyear = {2018}\r\n}\r\n","author_short":["Cox, H.","Mizrahi, V."],"key":"Cox2018","id":"Cox2018","bibbaseid":"cox-mizrahi-thecomingofageofdrugsusceptibilitytestingfortuberculosis-2018","role":"author","urls":{"Paper":"http://www.nejm.org/doi/10.1056/NEJMe1811861"},"keyword":["editorial","fund_not_ack"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh"],"keywords":["editorial","fund_not_ack"],"search_terms":["coming","age","drug","susceptibility","testing","tuberculosis","cox","mizrahi"],"title":"The coming of age of drug-susceptibility testing for tuberculosis","year":2018}